Shareholders of Capricor Therapeutics Urged to Act Before September 2025 Deadline
Shareholders of Capricor Therapeutics Urged to Act
Investors holding shares in Capricor Therapeutics, Inc. (NASDAQ: CAPR) have been advised by The Gross Law Firm to come forward before September 15, 2025, to discuss their legal rights concerning recent class action developments.
Background on Capricor Therapeutics
Capricor is a biotechnology firm focused on cell therapy for serious heart conditions, particularly cardiomyopathy associated with Duchenne muscular dystrophy (DMD). Shares of Capricor experienced significant fluctuations following disclosures regarding its lead drug candidate, deramiocel.
Legal Notice to Shareholders
The Gross Law Firm is actively notifying shareholders who purchased Capricor shares during the class period from October 9, 2024, to July 10, 2025. Investors who wish to explore a lead plaintiff appointment in the forthcoming class action are particularly encouraged to reach out. Importantly, being appointed as a lead plaintiff is not a prerequisite for participation in any financial recovery if the case succeeds.
The firm provided essential details regarding the allegations surrounding Capricor's disclosures—primarily how misinformation about the efficacy and safety of deramiocel was allegedly communicated to investors. During this period, shareholders were informed that Capricor was on track to secure approval from the U.S. Food and Drug Administration (FDA) for its drug candidate.
However, a pivotal turn occurred on July 11, 2025, when Capricor announced it received a Complete Response Letter (CRL) from the FDA, which denied its Biologics License Application (BLA). The letter cited insufficient evidence of drug effectiveness and highlighted the company’s failure to meet certain criteria in the Chemistry, Manufacturing, and Controls section. This news promptly caused Capricor's stock to plummet, with prices dropping from $11.40 to $7.64 per share within a single day.
Next Steps for Shareholders
Shareholders of Capricor are urged not to delay registering for this class action to ensure they can claim their rights effectively. By registering, they will also gain access to portfolio monitoring software that can provide updates about the case’s progression. The last date to register for potential lead plaintiff status is September 15, 2025, with no costs involved in participating.
Why Choose The Gross Law Firm?
The Gross Law Firm prides itself on being a recognized name in class action litigation, dedicated to safeguarding the rights of investors affected by corporate misconduct. With a strong reputation for pursuing justice against fraudulent activities, the firm emphasizes transparent business practices and corporate responsibility among companies. They seek recovery for investors who have suffered financial losses due to misleading statements or the concealment of critical information.
For further inquiries, investors can access the firm's dedicated platform for submissions or reach out directly through the contact information provided below.
Contact Information
- - The Gross Law Firm
New York, NY, 10018
Email: [email protected]
Phone: (646) 453-8903
In summary, now is a crucial time for shareholders in Capricor Therapeutics to engage with The Gross Law Firm to protect their interests.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.